A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs. The latest installment of the Campaign for Sustainable Rx Pricing’s “Second Opinion” series highlights how hospitals are subject to fixed reimbursements for the vast majority of care they provide, and the “true driver behind the rising costs is PhRMA’s willingness to do anything for an extra dollar, even if it means forcing patients to choose between paying for the medicines they need and their daily life necessities.” CSRxP, of which the AHA is a founding member, said it will continue to fact check PhRMA’s false claims and move forward with patient-focused solutions to increase transparency, promote competition and ensure a drug’s price is based on how well it works for patients. 
 

Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…
Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…
Headline
The AHA Aug. 17 provided comments to the Centers for Medicare & Medicaid Services on its proposed rule to codify in regulation the Medicare Drug Price…
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…